Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00192387 · ClinicalTrials.gov registry record · Phase 2
Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T)
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00192387 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 60 participants.
The verdict
NCT00192387, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The primary objective of this study was to determine the proportion of subjects, seronegative to all three strains of influenza, as defined by a serum hemagglutination inhibition antibodies (HAI) antibody titer of \<1:10, who shed each vaccine virus strain following a single dose of CAIV-T.
Interventions
- BIOLOGICAL CAIV-T, Liquid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2001-09 |
| Est. Completion | 2001-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00192387
The ClinicalTrials.gov registry entry for NCT00192387 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CAIV-T, Liquid is the first listed.
NCT00192387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00192387 about?
NCT00192387 is a clinical study titled "Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T)". The primary objective of this study was to determine the proportion of subjects, seronegative to all three strains of influenza, as defined by a serum hemagglutination inhibition antibodies (HAI) antibody titer of \<1:10, who shed each vaccine virus strain following a single dose of CAIV-T.
What is the current status of trial NCT00192387?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2001-09. Estimated completion is 2001-12.
What interventions are being tested in trial NCT00192387?
The interventions under investigation include: CAIV-T, Liquid (BIOLOGICAL).
Who is sponsoring clinical trial NCT00192387?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.